(Q51359217)

English

Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study.

scientific article published on 18 April 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22443183

Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22443183

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

10

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22443183

author name string

E S Hong

1

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22443183

A R Khang

2

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22443183

J W Yoon

3

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22443183

S M Kang

4

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22443183

S H Choi

5

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22443183

K S Park

6

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22443183

H C Jang

7

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22443183

H Shin

8

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22443183

G A Walford

9

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22443183

publication date

18 April 2012

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22443183

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22443183

14

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22443183

9

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22443183

795-802

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22443183

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Intensification lessons with modern premixes: from clinical trial to clinical practice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

SUIT, secretory units of islets in transplantation: An index for therapeutic management of islet transplanted patients and its application to type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral antidiabetic medications: a pilot study with sitagliptin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Diabetes in older adults: comparison of 1997 American Diabetes Association classification of diabetes mellitus with 1985 WHO classification.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Mechanisms of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Special considerations for treatment of type 2 diabetes mellitus in the elderly

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

The effects of pharmacologic agents for type 2 diabetes mellitus on body weight

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Insulin-associated weight gain in diabetes--causes, effects and coping strategies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Combination of insulin and metformin in the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Severe hypoglycemia and risks of vascular events and death

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Effects of intensive glucose lowering in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2012.01600.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2012.01600.X

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22443183

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22443183

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51359217&oldid=1704427198"